Knockdown of Livin inhibits growth and invasion of gastric cancer cells through blockade of the MAPK pathway in vitro and in vivo

J.-m. Ou, Bin Ye, M.-k. Qiu, Yuxing Dai, Qiwen Dong, Junjie Shen, Ping Dong, Xuefeng Wang, Y.-b. Liu, Zhiwei Quan, Zhongyuan FeiInternational Journal of Oncology 2013 · DOI

Abstract

Livin, a novel member of the human inhibitors of apoptosis protein family, has been shown to be critical for tumor progression and poor prognosis for several types of malignancies. However, limited reports exist regarding the biological functions of Livin in human gastric cancer (GC). The present study investigated the clinical significance of Livin and caspase-3 (CAS-3) in human GC using immunohistochemistry assay, and explore the potential using RNA interference to knockdown Livin expression, including the subsequent effects on tumor growth and invasion in GC cells in vitro and in vivo. Our results showed that the rate of positive expression of Livin was significantly higher in GC tissues compared to that in adjacent non-cancer tissues (ANCT) (64.1 vs. 30.8%, P<0.001), while CAS-3 was lower in GC tissues than in ANCT (33.3 vs. 66.7%, P=0.001). Livin expression was positively correlated with tumor differentiation and lymph node metastases (P=0.009; P=0.007), while CAS-3 was negatively correlated with them (P=0.036; P=0.002) in patients with GC. Furthermore, knockdown of Livin inhibited cell proliferative activities and invasive potential, and induced cell in situ apoptosis in GC cells, accompanied with decreased expression of p38 MAPK, VEGF and MMP-2 and increased expression of CAS-3. In addition, the tumor volumes in the SGC7901 subcutaneous nude mouse model treated with Lv-shLivin was significantly smaller compared to those of the PBS group (P<0.01). Taken together, our findings indicate that the expression of Livin is increased in human GC and correlates with tumor differentiation and lymph node metastases, while knockdown of Livin inhibits cell growth and invasion through blockade of the MAPK pathway in GC cells, suggesting that Livin may be a potential therapeutic target for the treatment of GC.

Introduction

Gastric cancer (GC) remains a major global health challenge, often characterized by a dismal five-year survival rate of less than 20%. A fundamental hallmark of cancer progression is the evasion of apoptosis, or programmed cell death. This study focuses on Livin, a member of the inhibitor-of-apoptosis protein (IAP) family. While known to be overexpressed in various malignancies, its specific role in gastric cancer was previously unclear. Researchers sought to determine if Livin could serve as a clinical biomarker for disease severity and a viable therapeutic target by investigating its interaction with Caspase-3 (CAS-3)—the "executioner" protein of apoptosis—and the MAPK pathway, which regulates cell growth and survival.

Methods

The researchers employed a multi-tiered experimental approach:

  • Clinical Correlation: Analysis of 78 pairs of human gastric cancer tissues and adjacent non-cancer tissues (ANCT) using immunohistochemistry (IHC).
  • Gene Silencing (RNAi): Use of a lentiviral vector carrying short hairpin RNA (Lv-shLivin) to "knock down" Livin expression in the SGC-7901 gastric cancer cell line.
  • In Vitro and In Vivo Assays: Functional impacts were measured via MTT (proliferation), Transwell (invasion), and TUNEL (apoptosis) assays, alongside a subcutaneous xenograft model in nude mice to observe tumor volume changes.
  • Molecular Profiling: Quantitative real-time PCR and Western blotting were used to track changes in downstream signaling molecules, including p38 MAPK, VEGF (angiogenesis), and MMP-2 (tissue remodeling).

Key Results and Insights

The Livin/CAS-3 Inverse Relationship

Clinical data revealed a clear inverse relationship between Livin and CAS-3. Livin was present in 64.1% of GC tissues compared to only 30.8% of normal tissues ($P<0.001$). Conversely, CAS-3 expression was significantly lower in cancerous tissues. High Livin expression levels correlated significantly with poor tumor differentiation and lymph node metastasis, suggesting its utility in staging cancer aggressiveness.

Immunohistochemical staining of Livin and CAS-3 in gastric cancer tissues showing the inverse relationship between the two proteins.

Inhibition of Growth and Invasion via MAPK Blockade

Knocking down Livin significantly reduced cell proliferation and invasive potential. In the mouse model, tumors treated with Lv-shLivin were significantly smaller in both volume and weight compared to controls ($P<0.01$).

The study's most significant mechanistic finding is that silencing Livin downregulates the p38 MAPK pathway. This blockade subsequently reduces the expression of VEGF, cutting off potential blood supply, and MMP-2, reducing the tumor's ability to invade surrounding tissues.

Knockdown of Livin (shLivin) leads to a significant decrease in mRNA and protein levels of both p38 MAPK and its phosphorylated form (p-p38 MAPK).

Discussion and Future Directions

These findings indicate that Livin is a critical driver of gastric cancer progression. By silencing Livin, researchers were able to "unleash" CAS-3-mediated apoptosis and block the MAPK signaling pathway, effectively inhibiting tumor growth and metastasis.

While promising, the study was primarily conducted on a single cell line (SGC-7901). Future research should explore these effects across broader gastric cancer subtypes and focus on developing clinically viable delivery systems for RNAi. Ultimately, Livin represents a potent target for "apoptotic sensitization," potentially making tumors more susceptible to traditional chemotherapy.

Summary updated

Abstract

Livin, a novel member of the human inhibitors of apoptosis protein family, has been shown to be critical for tumor progression and poor prognosis for several types of malignancies. However, limited reports exist regarding the biological functions of Livin in human gastric cancer (GC). The present study investigated the clinical significance of Livin and caspase-3 (CAS-3) in human GC using immunohistochemistry assay, and explore the potential using RNA interference to knockdown Livin expression, including the subsequent effects on tumor growth and invasion in GC cells in vitro and in vivo. Our results showed that the rate of positive expression of Livin was significantly higher in GC tissues compared to that in adjacent non-cancer tissues (ANCT) (64.1 vs. 30.8%, P<0.001), while CAS-3 was lower in GC tissues than in ANCT (33.3 vs. 66.7%, P=0.001). Livin expression was positively correlated with tumor differentiation and lymph node metastases (P=0.009; P=0.007), while CAS-3 was negatively correlated with them (P=0.036; P=0.002) in patients with GC. Furthermore, knockdown of Livin inhibited cell proliferative activities and invasive potential, and induced cell in situ apoptosis in GC cells, accompanied with decreased expression of p38 MAPK, VEGF and MMP-2 and increased expression of CAS-3. In addition, the tumor volumes in the SGC7901 subcutaneous nude mouse model treated with Lv-shLivin was significantly smaller compared to those of the PBS group (P<0.01). Taken together, our findings indicate that the expression of Livin is increased in human GC and correlates with tumor differentiation and lymph node metastases, while knockdown of Livin inhibits cell growth and invasion through blockade of the MAPK pathway in GC cells, suggesting that Livin may be a potential therapeutic target for the treatment of GC.
BibTeX
@article{ou2013knockdown,
  author = {J.-M. OU and Bin Ye and M.-K. QIU and Yuxing Dai and Qiwen Dong and Junjie Shen and Ping Dong and Xuefeng Wang and Y.-B. LIU and Zhiwei Quan and Zhongyuan Fei},
  title = {{Knockdown of Livin inhibits growth and invasion of gastric cancer cells through blockade of the MAPK pathway in vitro and in vivo}},
  journal = {International Journal of Oncology},
  year = {2013},
  doi = {10.3892/ijo.2013.2171},
}
Figure